Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Smith & Nephew PLC (SN)

London
Currency in GBP
Disclaimer
1,094.50
+1.50(+0.14%)
Real-time Data
SN Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
1,084.501,095.00
52 wk Range
887.001,244.50
Bid/Ask
1,094.00 / 1,094.50
Prev. Close
1,093
Open
1,089.5
Day's Range
1,084.5-1,095
52 wk Range
887-1,244.5
Volume
787,787
Average Volume (3m)
2,402,158
1-Year Change
15.76%
Fair Value
Unlock
Fair Value Upside
Unlock
SN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
1,729.19
Upside
+58.68%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Compare SN to Peers and Sector

Metrics to compare
SN
Peers
Sector
Relationship
P/E Ratio
40.8x33.9x−0.6x
PEG Ratio
1.020.110.00
Price/Book
2.4x3.3x2.6x
Price / LTM Sales
2.2x3.5x3.2x
Upside (Analyst Target)
26.7%77.5%48.5%
Fair Value Upside
Unlock−3.2%7.8%Unlock

People Also Watch

3,248.00
III
+0.03%
3,564.00
REL
+0.42%
754.00
WPP
-0.24%
3,880.5
EXPN
+0.64%

FAQ

What Is the Smith & Nephew (SN) Stock Price Today?

The Smith & Nephew stock price today is 1,094.50

What Stock Exchange Does Smith & Nephew Trade On?

Smith & Nephew is listed and trades on the London stock exchange.

What Is the Stock Symbol for Smith & Nephew?

The stock symbol for Smith & Nephew is "SN."

What Is the Smith & Nephew Market Cap?

As of today, Smith & Nephew market cap is 9.52B.

What is Smith & Nephew Earnings Per Share?

The Smith & Nephew EPS is 0.35.

What Is the Next Smith & Nephew Earnings Date?

Smith & Nephew will release its next earnings report on 31 Oct 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.